Abstract：Interleukin-37 (IL-37),a member of the interleukin-1 family,is a novel inflammatory suppressor with negative feedback regulation.It is mainly derived from epithelial cells,monocytes and macrophages and can be expressed in many normal tissues,it is closely related to tumor and inflammation in clinic.By reducing the expression of Proinflammatory cytokine and chemokines and increasing the expression of immunosuppressive factors,IL-37 has a significant regulatory effect on a variety of inflammatory and immune related diseases,and by inhibiting angiogenesis,inhibition of tumor proliferation,Migration,so as to play an anti-tumor role.Clinical application of IL-37 can diagnose disease,monitor the progress of disease and control the occurrence and development of disease.
邹晨兮； 曾吉； 范芳华； 李一萌； 刘晶 王琪. 白介素-37与临床疾病关系的研究进展[J]. 中国当代医药, 2022, 29(3): 21-24.
ZOU Chenxi ；ZENG Ji ；FAN Fanghua ；LI Yimeng； LIU Jing ；WANG Qi. Research progress on the relationship between IL-37 and clinical diseases. 中国当代医药, 2022, 29(3): 21-24.
Eleanor D，John E，Martin J.Annotating genes with potential roles in the immune system：six new members of the IL-1 family[J].Trends Immunol，2001，22（10）：533-536.
[3]
Shuai X，Weimin L，Tong Y，et al.Expression of IL-37 contributes to the immunosuppressive property of human CD4+，CD25+regulatory T cells[J].Sci Rep，2015，5：14478.
[4]
Fonseca G，Furuzawa J，Yamamo JK.Interleukin 35（IL-35）and IL-37：intestinal and peripheral expression by T and B regulatory cells in patients with inflammatory bowel disease[J].Cytokine，2015，75（2）：389-402.
Li Y，Zhao M，Guo C，et al.Intracellular mature IL-37 suppresses tumor metastasis via inhibiting Rac1 activation[J].Oncogene，2018，37（8）：1095-1106.
[16]
Slattery ML，Mullany LE，Sakoda L，et al.The NF-κB signalling pathway in colorectal cancer：associations between dysregulated gene and miRNA expression [J].J Cancer Res Clin Oncol，2018，144（2）：269-283.
Yan XF，Zhao J，Zhang R.Interleukin-37 mediates the antitumor activity in colon cancer through β-catenin suppression[J].Oncotarget，2017，8（30）：49064-49075.
[19]
Yu B，Wang J，He C，et al.Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer[J].Exp Ther Med，2017，14（1）：831-840.
[20]
Tong YS，Juan T，Xi LZ，et al.Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage Ⅲnon-small cell lung cancer[J].J Tranl Med，2017，15（1）：221.
[21]
Guanqun G，Aiqin W，Jingyue Y，et al.Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer[J].J Exp Clin Cancer Res，2016，35（1）：13.
[22]
Li ZC，Sun MD，Zheng YQ，et al.The Low Expression of IL-37 Involved in Multiple Myeloma Associated Angiogenesis[J].Med Sci Monit，2016，3（22）：4164-4168.
[23]
Yu M，Ying Z，Huey YT，et al.The indirect antiangiogenic effect of IL-37 in the tumor microenvironment[J].J Leukoc Biol，2020，107（5）：783-796.
Mahmoud EH，Fawzy A，A Elshimy RA.Serum MicroRNA-21 Negatively Relates to Expression of Programmed Cell Death-4 in Patients with Epithelial Ovarian Cancer[J].Asian Pac J Cancer Prev，2018，19（1）：33-38.
京公网安备 11010502046607号